Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16785169 | 0.84 | AOC3 (0.50) | ITGB3ITGA2BDRD2DRD3AOC3 | |
| SCHEMBL16785186 | 0.80 | AOC3 (0.68) | ITGB3ITGA2BDRD2TP53LMNA | |
| SCHEMBL12524392 | 0.78 | AOC3 (0.69) | ITGB3ITGA2BKDM4ETP53USP2 | |
| SCHEMBL17656753 | 0.78 | ITGB3 (0.63) | ITGB3ITGA2BDRD2DRD3HSD17B10 | |
| SCHEMBL16785024 | 0.77 | AOC3 (0.48) | ITGB3ITGA2BDRD2DRD3TSHR | |
| SCHEMBL16785122 | 0.77 | AOC3 (0.70) | ITGB3DRD2DRD3HSD17B10MAPT | |
| SCHEMBL12524423 | 0.75 | AOC3 (0.71) | ITGB3ITGA2BAOC3 | |
| SCHEMBL16785195 | 0.74 | AOC3 (0.49) | ITGB3ITGA2BMAPTKDM4EAOC3 | |
| SCHEMBL12526363 | 0.74 | DRD2 (0.56) | ITGB3ITGA2BDRD2DRD3HSD17B10 | |
| SCHEMBL16784952 | 0.74 | AOC3 (0.54) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3002278-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| US-20150203480-A1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-9051283-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| WO-2012124696-A1 | GUANIDINE COMPOUND | アステラス製薬株式会社 (JP) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203480-A1 | GUANIDINE COMPOUND | GUCY1A1, VAPA, VAPB | ITGB3 3336/4885ITGA2B 3594/4885DRD2 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.